Dose–volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study
R. Mazeron(Centre Léon Bérard), Richard Pötter(Medical University of Vienna), Peter Hoskin(University of Manchester), Ina M. Jürgenliemk‐Schulz(University Medical Center Utrecht), Jacob Christian Lindegaard(Aarhus University Hospital), Kathrin Kirchheiner(Comprehensive Cancer Center Vienna), Lars Fokdal(Aarhus University Hospital), Barbara Šegedin(Institute of Oncology Ljubljana), Christine Haie-Méder(Institut Gustave Roussy), Kari Tanderup(Aarhus University), Christian Kirisits(Comprehensive Cancer Center Vienna), Noha Jastaniyah(Vienna General Hospital), Wolfgang Dörr(Goethe University Frankfurt), Petra Georg(Medical University of Vienna), Umesh Mahantshetty(Homi Bhabha National Institute)
Cited by 266
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology
|Radiotherapy and Oncology|2006|1.6k
Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group☆ (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV
|Radiotherapy and Oncology|2005|1.5k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
|Clinical and Translational Radiation Oncology|2018|932